Literature DB >> 15727946

Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats.

Christine L Oltman1, Lawrence J Coppey, Jill S Gellett, Eric P Davidson, Donald D Lund, Mark A Yorek.   

Abstract

We have examined the progression of vascular and neural deficits in Zucker rats, Zucker diabetic fatty (ZDF) diabetic rats, and age-matched lean ZDF rats from 8 to 40 wk of age. Both the ZDF diabetic and Zucker rats were glucose intolerant at 8 wk of age. The Zucker rats did not become hyperglycemic but were hyperinsulinemic through 32 wk of age. All ZDF diabetic rats became hyperglycemic by 8 wk of age. Through their life span, serum free fatty acids and triglycerides levels were significantly higher in Zucker and ZDF diabetic rats compared with age-matched lean ZDF rats. After 24 and 28 wk of age, endoneurial blood flow was significantly decreased in ZDF diabetic and Zucker rats. Motor nerve conduction velocity was significantly decreased after 12-14 wk of age in ZDF diabetic rats and at 32 wk of age in Zucker rats. ACh-mediated vascular relaxation of epineurial arterioles of the sciatic nerve was impaired after 8-10 wk of age in ZDF diabetic rats and after approximately 16 wk of age in Zucker rats. In contrast, vascular relaxation mediated by calcitonin gene-related peptide was impaired significantly after 28 wk of age in ZDF diabetic rats but not impaired in Zucker rats up to 40 wk of age. Markers of oxidative stress were differentially elevated in ZDF diabetic rats and Zucker rats. These data indicate that vascular and neural dysfunction develops in both Zucker and ZDF diabetic rats but at different rates, which may be the result of hyperglycemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15727946     DOI: 10.1152/ajpendo.00594.2004

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  53 in total

1.  Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice.

Authors:  Lawrence Coppey; Eric Davidson; Bao Lu; Craig Gerard; Mark Yorek
Journal:  Neuropharmacology       Date:  2010-09-16       Impact factor: 5.250

2.  Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction.

Authors:  Eric P Davidson; Lawrence J Coppey; Nigel A Calcutt; Christine L Oltman; Mark A Yorek
Journal:  Diabetes Metab Res Rev       Date:  2010-05       Impact factor: 4.876

Review 3.  Exercise as Therapy for Diabetic and Prediabetic Neuropathy.

Authors:  J Robinson Singleton; A Gordon Smith; Robin L Marcus
Journal:  Curr Diab Rep       Date:  2015-12       Impact factor: 4.810

Review 4.  Early diabetic neuropathy: triggers and mechanisms.

Authors:  Maxim Dobretsov; Dmitry Romanovsky; Joseph R Stimers
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

5.  In Zucker diabetic fatty rats, subclinical diabetic neuropathy increases in vivo lidocaine block duration but not in vitro neurotoxicity.

Authors:  Philipp Lirk; Magdalena Flatz; Ingrid Haller; Barbara Hausott; Stephan Blumenthal; Markus F Stevens; Suzuko Suzuki; Lars Klimaschewski; Peter Gerner
Journal:  Reg Anesth Pain Med       Date:  2012 Nov-Dec       Impact factor: 6.288

6.  Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications.

Authors:  Eric P Davidson; Lawrence J Coppey; Amey Holmes; Brian Dake; Mark A Yorek
Journal:  Eur J Pharmacol       Date:  2011-07-28       Impact factor: 4.432

7.  Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats.

Authors:  Christine L Oltman; Eric P Davidson; Lawrence J Coppey; Travis L Kleinschmidt; Brian Dake; Mark A Yorek
Journal:  Eur J Pharmacol       Date:  2010-10-30       Impact factor: 4.432

8.  Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited.

Authors:  Irina G Obrosova; Viktor R Drel; Pal Pacher; Olga Ilnytska; Zhong Q Wang; Martin J Stevens; Mark A Yorek
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

9.  NS309 restores EDHF-type relaxation in mesenteric small arteries from type 2 diabetic ZDF rats.

Authors:  E Brøndum; H Kold-Petersen; U Simonsen; Christian Aalkjaer
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

10.  Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction.

Authors:  C L Oltman; E P Davidson; L J Coppey; T L Kleinschmidt; M A Yorek
Journal:  Diabetes Obes Metab       Date:  2008-06-16       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.